| Metric | FY2025 | FY2024 | FY2023 | FY2023 | FY2022 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $31.8M+37.9% | $23.1M+201.9% | $7.6M+23.3% | $6.2M | $0 | — |
| Cost of revenue | $25.7M+2.4% | $25.1M-60.2% | $63.1M+171.4% | $23.2M+1081.4% | $2.0M-41.7% | $3.4M |
| Gross profit (loss) | $6.1M+398.5% | -$2.0M+96.3% | -$55.4M-225.3% | -$17.0M-766.1% | -$2.0M | — |
| Research and development | $110.3M-11.4% | $124.5M+40.9% | $88.4M+52.3% | $58.1M+53.4% | $37.9M+162.1% | $14.4M |
| Selling, general and administrative | $73.0M-1.7% | $74.3M-6.0% | $79.0M+52.0% | $52.0M+75.0% | $29.7M+420.0% | $5.7M |
| Impairment of equipment | $0 | $0-100.0% | $4.4M-10.4% | $4.9M | $0 | — |
| Restructuring cost | $0-100.0% | $41.8M+1283.9% | $3.0M | $0 | $0 | — |
| Total operating expenses | $183.4M-23.8% | $240.6M+37.6% | $174.8M+52.1% | $114.9M+70.1% | $67.6M+187.1% | $23.5M |
| Loss from operations | -$177.3M+27.0% | -$242.7M-5.4% | -$230.3M-74.5% | -$132.0M-89.8% | -$69.5M-195.5% | -$23.5M |
| Change in fair value of common stock warrants | $21.8M+78.3% | $12.2M+98.1% | $6.2M-91.8% | $75.2M+233.9% | -$56.1M-307.1% | -$13.8M |
| Gain on bargain purchase of assets | $4.8M | $0 | $0 | — | — | — |
| Interest income | $13.0M+5.4% | $12.3M-12.4% | $14.1M+169.0% | $5.2M+14037.8% | $37K | — |
| Interest expense | -$21.6M-218.2% | -$6.8M-52.3% | -$4.5M | $0+100.0% | -$187K | — |
| Other income (expense), net | $1.3M+40.6% | $954K+413.8% | -$304K-463.0% | -$54K+11.5% | -$61K-232.6% | $46K |
| Total other income (expense), net | $19.3M+3.2% | $18.7M+21.0% | $15.5M-80.7% | $80.4M+242.6% | -$56.4M-249.6% | -$16.1M |
| Loss before income tax benefit | -$157.9M+29.5% | -$223.9M-4.3% | -$214.8M-316.0% | -$51.6M+59.0% | -$125.9M | — |
| Income tax benefit | -$1.3M+5.7% | -$1.4M-119.9% | -$633K | $0 | $0 | — |
| Net loss | -$156.6M+29.6% | -$222.5M-3.9% | -$214.1M-314.8% | -$51.6M+59.0% | -$125.9M-217.5% | -$39.6M |
| Net gain (loss) attributable to non-controlling interests | $134K+145.7% | -$293K-380.3% | -$61K | $0 | $0 | — |
| Net loss attributable to Enovix | -$156.7M+29.5% | -$222.2M-3.8% | -$214.1M-314.7% | -$51.6M+59.0% | -$125.9M-217.5% | -$39.6M |
| Net loss per share attributable to Enovix shareholders, basic (in dollars per share) | -$0.75+37.0% | -$1.19+6.3% | -$1.27-273.5% | -$0.34+68.2% | -$1.07 | — |
| Weighted average number of common shares outstanding, basic (in shares) | 207.64B+11.6% | 186.04B+10.0% | 169.06B+10.6% | 152.92B+130355.3% | 117.2M | — |
| Net loss per share attributable to Enovix shareholders, diluted (in dollars per share) | -$0.75+37.0% | -$1.19+8.5% | -$1.30-58.5% | -$0.82+23.4% | -$1.07 | — |
| Weighted average number of common shares outstanding, diluted (in shares) | 207.64B+11.6% | 186.04B+9.7% | 169.57B+10.0% | 154.15B+131405.6% | 117.2M | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.